Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes

Shi Wen Kuo, Pei-Dee, Yi Jen Hung, An-Tsz Hsieh, Ling Yi Wu, Chang Hsun Hsieh, Chih Tsueng He, Tsao Chin Yang, Wei Cheng Lian

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles. Methods: A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test. Results: The changes in standing and supine blood pressure (BP) were significant (154.7 ± 9.4/94 ± 2.9 mm Hg v 134.4 ± 5.1/82.4 ± 5 mm Hg and 155 ± 9.8/94.6 ± 3.6 mm Hg v 135.1 ± 4.9/82.1 ± 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 ± 19.3/87.6 ± 11.3 mm Hg v 135.7 ± 12.6/79.6 ± 9 mm Hg) but also the whole-day mean median arterial pressure (109 ± 12.7 mm Hg v 98.7 ± 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy. Conclusions: Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients' lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.

Original languageEnglish
Pages (from-to)623-628
Number of pages6
JournalAmerican Journal of Hypertension
Volume16
Issue number8
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

Fingerprint

Indapamide
Type 2 Diabetes Mellitus
Blood Pressure
Placebos
Blood Pressure Monitors
Glucose
Therapeutics
Glucose Tolerance Test
Lipids
Fasting
Insulin
Hypertension
Hyperuricemia
Potassium Chloride
Hypokalemia
Blood Urea Nitrogen
Aspartate Aminotransferases
Uric Acid
Alanine Transaminase
Lipid Metabolism

Keywords

  • Diabetes mellitus
  • Hypertension
  • Indapamide SR

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. / Kuo, Shi Wen; Pei-Dee; Hung, Yi Jen; Hsieh, An-Tsz; Wu, Ling Yi; Hsieh, Chang Hsun; He, Chih Tsueng; Yang, Tsao Chin; Lian, Wei Cheng.

In: American Journal of Hypertension, Vol. 16, No. 8, 01.08.2003, p. 623-628.

Research output: Contribution to journalArticle

Kuo, Shi Wen ; Pei-Dee ; Hung, Yi Jen ; Hsieh, An-Tsz ; Wu, Ling Yi ; Hsieh, Chang Hsun ; He, Chih Tsueng ; Yang, Tsao Chin ; Lian, Wei Cheng. / Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. In: American Journal of Hypertension. 2003 ; Vol. 16, No. 8. pp. 623-628.
@article{5b693f1fb84540cb99f3ee4e1de5d340,
title = "Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes",
abstract = "Background: To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles. Methods: A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test. Results: The changes in standing and supine blood pressure (BP) were significant (154.7 ± 9.4/94 ± 2.9 mm Hg v 134.4 ± 5.1/82.4 ± 5 mm Hg and 155 ± 9.8/94.6 ± 3.6 mm Hg v 135.1 ± 4.9/82.1 ± 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 ± 19.3/87.6 ± 11.3 mm Hg v 135.7 ± 12.6/79.6 ± 9 mm Hg) but also the whole-day mean median arterial pressure (109 ± 12.7 mm Hg v 98.7 ± 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy. Conclusions: Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients' lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.",
keywords = "Diabetes mellitus, Hypertension, Indapamide SR",
author = "Kuo, {Shi Wen} and Pei-Dee and Hung, {Yi Jen} and An-Tsz Hsieh and Wu, {Ling Yi} and Hsieh, {Chang Hsun} and He, {Chih Tsueng} and Yang, {Tsao Chin} and Lian, {Wei Cheng}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0895-7061(03)00896-3",
language = "English",
volume = "16",
pages = "623--628",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes

AU - Kuo, Shi Wen

AU - Pei-Dee,

AU - Hung, Yi Jen

AU - Hsieh, An-Tsz

AU - Wu, Ling Yi

AU - Hsieh, Chang Hsun

AU - He, Chih Tsueng

AU - Yang, Tsao Chin

AU - Lian, Wei Cheng

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles. Methods: A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test. Results: The changes in standing and supine blood pressure (BP) were significant (154.7 ± 9.4/94 ± 2.9 mm Hg v 134.4 ± 5.1/82.4 ± 5 mm Hg and 155 ± 9.8/94.6 ± 3.6 mm Hg v 135.1 ± 4.9/82.1 ± 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 ± 19.3/87.6 ± 11.3 mm Hg v 135.7 ± 12.6/79.6 ± 9 mm Hg) but also the whole-day mean median arterial pressure (109 ± 12.7 mm Hg v 98.7 ± 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy. Conclusions: Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients' lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.

AB - Background: To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles. Methods: A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test. Results: The changes in standing and supine blood pressure (BP) were significant (154.7 ± 9.4/94 ± 2.9 mm Hg v 134.4 ± 5.1/82.4 ± 5 mm Hg and 155 ± 9.8/94.6 ± 3.6 mm Hg v 135.1 ± 4.9/82.1 ± 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 ± 19.3/87.6 ± 11.3 mm Hg v 135.7 ± 12.6/79.6 ± 9 mm Hg) but also the whole-day mean median arterial pressure (109 ± 12.7 mm Hg v 98.7 ± 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy. Conclusions: Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients' lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.

KW - Diabetes mellitus

KW - Hypertension

KW - Indapamide SR

UR - http://www.scopus.com/inward/record.url?scp=0041366834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041366834&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(03)00896-3

DO - 10.1016/S0895-7061(03)00896-3

M3 - Article

VL - 16

SP - 623

EP - 628

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 8

ER -